Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
    Liu, Xingyu
    Zhao, Yingjun
    Jiao, Xiaofei
    Yu, Yang
    Li, Ruyuan
    Zeng, Shaoqing
    Chi, Jianhua
    Ma, Guanchen
    Huo, Yabing
    Li, Ming
    Peng, Zikun
    Liu, Jiahao
    Zhou, Qi
    Zou, Dongling
    Wang, Li
    Li, Qingshui
    Wang, Jing
    Yao, Shuzhong
    Chen, Youguo
    Ma, Ding
    Hu, Ting
    Gao, Qinglei
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [42] Comparison of neoadjuvant chemotherapy versus primary cytoreductive surgery in stage III-IV epithelial ovarian cancer: a retrospective study
    Sirma, Tugce
    Taskin, Salih
    Ortac, Ugur Firat
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2025, 46 (01) : 94 - 103
  • [43] A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
    May, Taymaa
    Comeau, Robyn
    Sun, Ping
    Kotsopoulos, Joanne
    Narod, Steven A.
    Rosen, Barry
    Ghatage, Prafull
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) : 668 - 674
  • [44] Management of Advanced Staged Ovarian Cancer in a National Cancer Center: Comparison of the Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
    Kovacevic, Nina
    Skof, Erik
    Cilensek, Ines
    Merlo, Sebastjan
    CURRENT WOMENS HEALTH REVIEWS, 2021, 17 (03) : 267 - 273
  • [45] Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis
    Chiofalo, Benito
    Bruni, Simone
    Certelli, Camilla
    Sperduti, Isabella
    Baiocco, Ermelinda
    Vizza, Enrico
    MINERVA MEDICA, 2019, 110 (04) : 330 - 340
  • [46] Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience
    Bilici, Ahmet
    Salepci, Taflan
    Dane, Faysal
    Gumus, Mahmut
    Ustaalioglu, Bala Basak Oven
    Seker, Mesut
    Salman, Tarik
    Turan, Cem
    Unal, Orhan
    Yaylaci, Mustafa
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2010, 282 (04) : 417 - 425
  • [47] Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
    Coleridge, Sarah L.
    Bryant, Andrew
    Kehoe, Sean
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (07):
  • [48] Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States
    Cole, Ashley L.
    Austin, Anna E.
    Hickson, Ryan P.
    Dixon, Matthew S.
    Barber, Emma L.
    CANCER EPIDEMIOLOGY, 2018, 55 : 8 - 16
  • [49] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Lee, Jessica
    Curtin, John P.
    Muggia, Franco M.
    Pothuri, Bhavana
    Boyd, Leslie R.
    Blank, Stephanie V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 55 - 63
  • [50] Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    Lin, Hao
    Chen, Wen-Hsin
    Wu, Chen-Hsuan
    Ou, Yu-Che
    Chen, Yu-Jen
    Chen, Ying-Yi
    Lin, Yu-Han
    Fu, Hung-Chun
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5413 - 5422